Pasquale Sansone

Prof. Pasquale Sansone

Department of Women, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
WHWalid Habre
Walid Habre
NDNicola Disma
Nicola Disma
KVKatalin Virag
Katalin Virag
KBKarin Becke
Karin Becke
MJMartin Jöhr
Martin Jöhr
PHPierre Harlet
Pierre Harlet

21 March 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Caterina AurilioCaterina Aurilio
Caterina Aurilio
Pasquale SansonePasquale Sansone
Pasquale Sansone
MBManlio Barbarisi
Manlio Barbarisi
Vincenzo PotaVincenzo Pota
Vincenzo Pota
LGLuca Gregorio Giaccari
Luca Gregorio Giaccari
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
Carbapenem antibiotics are the most effective antimicrobials for the treatment of infections caused by the most resistant bacteria. They belong to the category of β-lactams that include the penicillins, cephalosporins, monobactams and carbapenems. This class of antimicrobials has a broader spectrum of activity than most other beta-lactams antibiotics and are the most effective against Gram-positive and Gram-negative bacteria. All β-lactams antibiotics have a similar molecular structure: the carbapenems together with the β-lactams. This combination gives an extraordinary stability to the molecule against the enzymes inactivating the β-lactams. They are safe to use and therefore widespread use in many countries has given rise to carbapenem resistance which is a major global public health problem. The carbapenem resistance in some species is intrinsic and consists of the capacity to resist the action of antibiotics with several mechanisms: for the absence of a specific target, or an intrinsic difference in the composition of cytoplasmatic membrane or the inability to cross the outer membrane. In addition to intrinsic resistance, bacteria can develop resistance to antibiotics with several mechanisms that can be gathered in three main groups. The first group includes antibiotics with poor penetration into the outer membrane of bacterium or antibiotic efflux. The second includes bacteria that modify the target of the antibiotics through genetic mutations or post-translational modification of the target. The third includes bacteria that act with enzyme-catalyzed modification and this is due to the production of beta-lactamases, that are able to inactivate carbapenems and so called carbapenemases. In this review, we focus on the mode of action of carbapenem and the mechanisms of carbapenem resistance.

3 June 2021 in Life
Verified
Journal Article
Open access
PDF file
Roberto GiurazzaRoberto Giurazza
Roberto Giurazza
MMMaria Civita Mazza
Maria Civita Mazza
RARoberto Andini
Roberto Andini
Pasquale SansonePasquale Sansone
Pasquale Sansone
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
Emanuele Durante-MangoniEmanuele Durante-Mangoni
Emanuele Durante-Mangoni
Antimicrobial resistance (AMR) remains one of the top public health issues of global concern. Among the most important strategies for AMR control there is the correct and appropriate use of antibiotics, including those available for the treatment of AMR pathogens. In this article, after briefly reviewing the most important and clinically relevant multi-drug-resistant bacteria and their main resistance mechanisms, we describe the emerging antimicrobial options for both MDR Gram-positive cocci and Gram-negative bacilli, including recently marketed agents, molecules just approved or under evaluation and rediscovered older antibiotics that have regained importance due to their antimicrobial spectrum. Specifically, emerging options for Gram-positive cocci we reviewed include ceftaroline, ceftobiprole, tedizolid, dalbavancin, and fosfomycin. Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol. An exciting scenario is opening today with the long awaited growing availability of novel molecules for the treatment of AMR bacteria. Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future.

15 June 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
Maria Beatrice PassavantiMaria Beatrice Passavanti
Maria Beatrice Passavanti
LNLorenzo De Nardis
Lorenzo De Nardis
FBFabio Bosco
Fabio Bosco
Pasquale SansonePasquale Sansone
Pasquale Sansone
CACaterina Aurilio
Caterina Aurilio

1 June 2006 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
Maria Caterina PaceMaria Caterina Pace
Maria Caterina Pace
LML. Mazzariello
L. Mazzariello
Maria Beatrice PassavantiMaria Beatrice Passavanti
Maria Beatrice Passavanti
Pasquale SansonePasquale Sansone
Pasquale Sansone
MBM. Barbarisi
M. Barbarisi
CAC. Aurilio
C. Aurilio

28 October 2017 in World Journal of Hepatology
Verified
Journal Article
Open access
Marco FioreMarco Fiore
Marco Fiore
Alberto MaraoloAlberto Maraolo
Alberto Maraolo
IGIvan Gentile
Ivan Gentile
GBGuglielmo Borgia
Guglielmo Borgia
SLSebastiano Leone
Sebastiano Leone
MPMaria Caterina Pace
Maria Caterina Pace
Spontaneous bacterial peritonitis (SBP) is the most common infection in end-stage liver disease patients. SBP is defined as an ascitic fluid infection with a polymorphonuclear leucocyte count ≥ 250/mm3 without an evident intra-abdominal surgically treatable source. Several mechanisms contribute to SBP occurrence, including translocation of gut bacteria and their products, reduced intestinal motility provoking bacterial overgrowth, alteration of the gut's barrier function and local immune responses. Historically, Gram-negative enteric bacteria have been the main causative agents of SBP, thereby guiding the empirical therapeutic choice. However, over the last decade, a worryingly increasing prevalence of Gram-positive and multi-drug resistant (MDR) SBP has been seen. Recently, the microbiological spectrum of SBP seems to have changed in Europe due to a high prevalence of Gram-positive bacteria (48%-62%). The overall proportion of MDR bacteria is up to 22%-73% of cases. Consequently, empirical therapy based on third-generation cephalosporins or amoxicillin/clavulanic acid, can no longer be considered the standard of care, as these drugs are associated with poor outcomes. The aim of this review is to describe, with an epidemiological focus, the evidence behind this rise in Gram-positive and MDR SBP from 2000 to present, and illustrate potential targeted therapeutic strategies. An appropriate treatment protocol should include daptomycin plus ceftaroline and meropenem, with prompt stepdown to a narrower spectrum when cultures and sensitivity data are available in order to reduce both cost and potential antibiotic resistance development.